Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT01088048 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

241

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma

Interventions

DRUG: Idelalisib
DRUG: Rituximab
DRUG: Bendamustine
DRUG: Ofatumumab
DRUG: Fludarabine
DRUG: Everolimus
DRUG: Bortezomib
DRUG: Chlorambucil
DRUG: Lenalidomide

Sponsor

Gilead Sciences